MSH2 and ovarian carcinoma: In contrast, increased mRNA expression of PMS2 is associated with improved overall survival in ovarian cancer [18], MSH2 fails to predict progression-free survival in bladder cancer and high MSH2 predicts improved overall survival in Stage I–II colon cancer [16].